SG11202112399PA - Variant domains for multimerizing proteins and separation thereof - Google Patents
Variant domains for multimerizing proteins and separation thereofInfo
- Publication number
- SG11202112399PA SG11202112399PA SG11202112399PA SG11202112399PA SG11202112399PA SG 11202112399P A SG11202112399P A SG 11202112399PA SG 11202112399P A SG11202112399P A SG 11202112399PA SG 11202112399P A SG11202112399P A SG 11202112399PA SG 11202112399P A SG11202112399P A SG 11202112399PA
- Authority
- SG
- Singapore
- Prior art keywords
- separation
- variant domains
- multimerizing
- proteins
- multimerizing proteins
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000000926 separation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19173633 | 2019-05-09 | ||
PCT/NL2020/050298 WO2020226502A2 (en) | 2019-05-09 | 2020-05-08 | Variant domains for multimerizing proteins and separation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202112399PA true SG11202112399PA (en) | 2021-12-30 |
Family
ID=66476558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202112399PA SG11202112399PA (en) | 2019-05-09 | 2020-05-08 | Variant domains for multimerizing proteins and separation thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210054049A1 (pt) |
EP (1) | EP3966238A2 (pt) |
JP (1) | JP2022534674A (pt) |
KR (1) | KR20220017909A (pt) |
CN (2) | CN114702587A (pt) |
AR (1) | AR118898A1 (pt) |
AU (1) | AU2020268684A1 (pt) |
BR (1) | BR112021022405A2 (pt) |
CA (1) | CA3139402A1 (pt) |
IL (1) | IL287928A (pt) |
MA (1) | MA55884A (pt) |
MX (1) | MX2021013646A (pt) |
SG (1) | SG11202112399PA (pt) |
TW (1) | TW202108613A (pt) |
WO (1) | WO2020226502A2 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202003569A (zh) * | 2018-03-30 | 2020-01-16 | 荷蘭商美勒斯公司 | 多價抗體 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
US7135287B1 (en) * | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US6680209B1 (en) * | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
WO2005092925A2 (en) * | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
US9670269B2 (en) * | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
DK2202245T3 (en) * | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
KR102261586B1 (ko) | 2008-06-27 | 2021-06-08 | 메뤼스 엔.페. | 항체 생산 비-인간 포유동물 |
MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
EP3611187A1 (en) * | 2011-10-10 | 2020-02-19 | Xencor, Inc. | A method for purifying antibodies |
CN114163530A (zh) * | 2012-04-20 | 2022-03-11 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
EP2951203B1 (en) * | 2013-03-15 | 2019-05-22 | Xencor, Inc. | Heterodimeric proteins |
SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
CN106573986A (zh) * | 2014-07-29 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
MA41375A (fr) * | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
SG11201810470XA (en) * | 2016-06-10 | 2018-12-28 | Eisai R&D Man Co Ltd | Lysine conjugated immunoglobulins |
TW201920657A (zh) | 2017-07-06 | 2019-06-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
TW201920264A (zh) | 2017-07-06 | 2019-06-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的結合分子 |
IL271833B1 (en) | 2017-07-06 | 2024-05-01 | Merus Nv | Antibodies that regulate biological activity expressed by a cell |
EP3665198A1 (en) | 2017-08-09 | 2020-06-17 | Merus N.V. | Antibodies that bind egfr and cmet |
TW202003569A (zh) | 2018-03-30 | 2020-01-16 | 荷蘭商美勒斯公司 | 多價抗體 |
-
2020
- 2020-05-08 CN CN202210393772.0A patent/CN114702587A/zh active Pending
- 2020-05-08 AU AU2020268684A patent/AU2020268684A1/en active Pending
- 2020-05-08 WO PCT/NL2020/050298 patent/WO2020226502A2/en unknown
- 2020-05-08 AR ARP200101330A patent/AR118898A1/es unknown
- 2020-05-08 TW TW109115418A patent/TW202108613A/zh unknown
- 2020-05-08 SG SG11202112399PA patent/SG11202112399PA/en unknown
- 2020-05-08 BR BR112021022405A patent/BR112021022405A2/pt unknown
- 2020-05-08 MA MA055884A patent/MA55884A/fr unknown
- 2020-05-08 US US16/870,715 patent/US20210054049A1/en active Pending
- 2020-05-08 EP EP20727737.7A patent/EP3966238A2/en active Pending
- 2020-05-08 CA CA3139402A patent/CA3139402A1/en active Pending
- 2020-05-08 MX MX2021013646A patent/MX2021013646A/es unknown
- 2020-05-08 CN CN202080048983.XA patent/CN114430745A/zh active Pending
- 2020-05-08 KR KR1020217039330A patent/KR20220017909A/ko unknown
- 2020-05-08 JP JP2021566278A patent/JP2022534674A/ja active Pending
-
2021
- 2021-11-08 IL IL287928A patent/IL287928A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022534674A (ja) | 2022-08-03 |
WO2020226502A2 (en) | 2020-11-12 |
TW202108613A (zh) | 2021-03-01 |
WO2020226502A3 (en) | 2021-02-04 |
US20210054049A1 (en) | 2021-02-25 |
EP3966238A2 (en) | 2022-03-16 |
IL287928A (en) | 2022-01-01 |
MX2021013646A (es) | 2022-01-31 |
AU2020268684A1 (en) | 2021-12-09 |
AR118898A1 (es) | 2021-11-10 |
CN114702587A (zh) | 2022-07-05 |
BR112021022405A2 (pt) | 2022-04-19 |
CA3139402A1 (en) | 2020-11-12 |
KR20220017909A (ko) | 2022-02-14 |
WO2020226502A9 (en) | 2022-03-03 |
MA55884A (fr) | 2022-03-16 |
CN114430745A (zh) | 2022-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279510A (en) | Progranulin-FC polypeptide fusion proteins and their uses | |
IL279505A (en) | Chimeric transmembrane protein and its uses | |
IL278943A (en) | Multi-specificity binding proteins and improvements thereof | |
IL265489B (en) | Recombinant binding proteins and their uses | |
EP3287470A4 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
SG11202106771QA (en) | Single-molecule protein and peptide sequencing | |
ZA202100125B (en) | Novel fusion protein specific for cd137 and pd-l1 | |
IL284687A (en) | Novel fusion proteins specific for CD137 and GPC3 | |
IL284679A (en) | Multifunctional chimeric proteins and their use | |
ZA202100859B (en) | Recombinant protein variants | |
IL284772A (en) | Antibodies against variable *muc1 and uses thereof | |
GB201800334D0 (en) | Modified protein | |
SG11202110400QA (en) | Fusion protein and use thereof | |
EP3995508A4 (en) | NOVEL MODIFIED IMMUNOGLOBULIN FC FUSION PROTEIN AND USE THEREOF | |
SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
IL290715A (en) | nkg2d fusion proteins and their use | |
IL291618A (en) | Heterodimeric proteins | |
EP3816181A4 (en) | IMPROVED FVIII FUSION PROTEIN AND ITS USE | |
IL287928A (en) | Variant sites for multimerization of proteins and their separation | |
IL304317A (en) | tgf–beta–rii binding proteins | |
GB201919294D0 (en) | Antibodies or binding proteins | |
EP3976630A4 (en) | ACTRII-BINDING PROTEINS AND THEIR USES | |
EP3802566A4 (en) | PROTEINS AND THEIR USE FOR NUCLEOTIDE BINDING | |
EP3801485A4 (en) | PROTEIN AND PEPTIDE PURIFICATION PROCEDURES | |
EP3576767A4 (en) | RECOMBINANT PROTEINS AND USES THEREOF |